Study details
Enrolling now
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
InSightec
NCT IDNCT03671889ClinicalTrials.gov data as of Apr 2026
Target enrollment
150
Study length
about 7.3 years
Ages
50–85
Locations
10 sites in FL, NY, OH +2
About this study
This trial is testing a device to disrupt the blood-brain barrier in people with probable Alzheimer's disease. The goal is to evaluate if this device is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Blood Brain Barrier (BBB) Disruption
Primary goalDevice and procedure related adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Device and procedure related adverse events
Body systems
Neurology